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Abstract 
Controlled and sustained delivery of ophthalmic drugs continues to remain a 
major focus area in the field of pharmaceutical drug delivery with the 
emergence of new, more potent drugs and biological response modifiers that 
may also have very short biological half-lives. The major objective of clinical 
therapeutics is to provide and maintain adequate concentration of drugs at the 
site of action. In ocular drug delivery, the physiological constraints imposed 
by the protective mechanisms of the eye lead to poor absorption of drugs with 
very small fractions of the instilled dose penetrating the cornea and reaching 
the intraocular tissues. The anatomy, physiology, and biochemistry of the eye 
render this organ highly impervious to foreign substances. A significant 
challenge to the formulator is to circumvent the protective barriers of the eye 
without causing permanent tissue damage. Development of newer, more 
sensitive diagnostic techniques and novel therapeutic agents continue to 
provide ocular delivery systems with high therapeutic efficacy. Conventional 
ophthalmic solution, suspension, and ointment dosage forms no longer 
constitute optimal therapy for these indications. Nanoparticles and 
nanosuspensions are showing a better application as compare to conventional 
delivery sysyems. Polymer nanoparticles proposed are reported to be devoid 
of any irritant effect on cornea, iris, and conjunctiva and thus appear to be a 
suitable inert carrier for ophthalmic drug delivery. The benefits of having the 
drug in the form of a nanoparticulate suspension are: reduction in the amount 
of dose, drug release for a prolonged period of time, higher drug 
concentrations in the infected tissue, longer residence time of nanoparticles 
on the cornea surface, reduction systemic toxicity of drug. 
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Introduction  
Anatomical and Physiological Features of the Eye 
The eye is a unique organ for drug delivery. Many of 
its anatomical and physiological features interfere with 
the fate of the administered drug. First and foremost are 
blinking; tear secretion, and nasolacrimal drainage. Lid 
closure upon reflex blinking protects the eye from 
external   aggression.  Tears   permanently    wash    the  
 
surface of the eye and exert an anti-infectious activity 
by the lysozyme and immunoglobulins they contain. 
Eventually the lacrimal fluid is drained down the 
nasolacrimal pathways, then the pharynx and 
esophagus. This means that a portion of the drug is 
systematically delivered as if by the oral route. In 
addition, drug binding to tear proteins and to 
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conjunctival mucin also inactivates a portion of the 
administered dose. Further loss can arise through 
physical means. During administration, a part of an 
aqueous drop instilled in the patient’s cul-de-sac is 
inevitably lost by over flow/drainage, since the 
conjunctival pouch can accommodate only 
approximately 20 µL of added fluid [1-3]. 
Precorneal losses are the Achilles heel of 
traditional aqueous formulations and the largest part of 
drug loss following ophthalmic administration occurs 
in front of the eye. It is no wonder that many 
researchers were attracted by the challenge to improve 
topical ophthalmic formulations. Many attempts were 
made, but very few products actually completed a full 
development cycle and were made available for 
prescription. 
 
Drug Delivery to the Internal Regions of the Eye 
The goal of pharmaco-therapeutics is to treat a disease 
in a consistent and predictable fashion. An assumption 
is made that a correlation exists between the 
concentration of a drug at its intended site of action and 
the resulting pharmacological effect. Three main 
factors have to be considered when drug delivery is 
attempted to the intraocular tissues (4): (a) how to cross 
the blood-eye barrier (systemic to ocular) or cornea 
(external to ocular) to reach the site of action, (b) how 
to localize the pharmacodynamic action at the eye and 
minimize drug action on other tissues, and (c) how to 
prolong the duration of drug action such that the 
frequency of drug administration can be reduced. 
 
Eye Penetration of Drugs Administered Locally 
It is important if the drug is not intended to act on the 
external surface of the eye, then the active ingredient 
has to enter the eye. There is consensus that the most 
important route is transcorneal; however, a noncorneal 
route has been proposed and may contribute 
significantly to ocular bioavailability of some 
ingredients, e.g., Timolol and inulin [4]. In addition, 
the sclera has also been shown to have a high 
permeability for a series of ß-blocking drugs [5]. 
Schematically, the cornea is a sandwich comprising a 
hydrophilic layer, the stroma, between two lipophilic 
layers, the epithelium and the endothelium. The 
epithelium is composed of five to six layers of cells, 
whereas the endothelium is single-layered on the inner 
side of the cornea. In humans, the corneal thickness 
measures slightly more than 0.5 mm at the center and 
thickens a little at the periphery. The hydrophilic-
lipophilic nature of the cornea clearly indicates that to 
be well absorbed, active ingredients have to exhibit to 
some extent both lipophilic and hydrophilic properties. 
Precorneal tear film produced by tear secretion keeps 
the cornea moist, clear, and healthy and is spread by 
the motion of eyelids during blinking. Drugs acting on 
tear secretion, physicochemical status of the tear film, 
and blinking can modify transcorneal drug permeation. 
Indeed, a major issue is the ratio of precorneal 
disappearance/ transcorneal penetration. 
 
Eye Penetration of Systemically Administered 
Drugs 
It is of interest to reflect on the eye penetration of 
systemically administered drugs, mostly anti-infectious 
and anti-inflammatory drugs. There are blood-eye 
barriers. Aqueous humor is produced by the ciliary 
epithelium in the ciliary processes. It is frequently 
named an ultra filtrate, since the ciliary epithelium 
prevents the passage of large molecules, plasma 
proteins, and many antibiotics. Some molecules can be 
secreted in aqueous humor during its formation. 
Inflammation associated with injury, infection, or an 
ocular disease, e.g., uveitis, disrupts the blood–aqueous 
humor barrier and drugs enter the aqueous humor and 
reach the tissues of the anterior segment. There is a 
blood-retina barrier and there is one between blood and 
vitreous humor complicated by the high viscosity of the 
latter, which prevents diffusion of the drugs in the 
posterior part of the eye. Delivery of drugs to the 
posterior pole and to the retina is extremely difficult. 
 
Conventional ocular drug delivery constraints 
For the aliments of the eye, topical administration is 
usually preferred over systemic administration so as to 
avoid systemic toxicity, for rapid onset of action, and 
for decreasing the required dose. 
Though topical administration offers many advantages 
to treat disorders of anterior structures of the eye, it 
suffers from a serious disadvantage of poor 
bioavailability due to several biological factors, which 
exist to protect the eye and consequently limit the entry 
of ocular drugs. The constraints in topical delivery of 
the eye are discussed below.  
 
Pre-ocular retention   
It has been estimated that the human eye can hold 
approximately 30 µl of an ophthalmic solution without 
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overflow or spillage at the outer angle [10], while the 
volume delivered by most commercial ophthalmic eye 
drop dispensers is approximately 50 µl.  
Thus a large proportion of the drug is wasted due to 
administration of an excess volume. Following the 
removal of the excess solution from the front of the 
eye, a second mechanism of clearance prevails. The 
eye has an efficient system for tear turnover (1µl/min). 
The two mechanisms of clearance result in a biphasic 
profile for an instilled solution with a rapid initial 
clearance phase due to removal of excess fluid 
followed by a slower second phase due to tear turnover 
[11]. 
 
Corneal absorption  
The main route for intraocular absorption is across the 
cornea [12]. Two features, which render the cornea an 
effective barrier to drug absorption, are its small 
surface area and its relative impermeability. In contrast, 
the area of conjunctiva, which is a vascular thin 
mucous membrane covering the inside of the eyelids 
and the anterior sclera, in humans is approximately 17-
fold larger then the cornea. Moreover, it is also 
between 2 and 30 times more permeable to drugs than 
cornea [8]. Thus, following topical administration to 
the pre-ocular area, conjunctival drug absorption is an 
important loss factor that competes with corneal 
absorption [13]. 
Secondly in terms of drug delivery, the cornea is 
considered of three layers, which account for its poor 
permeability characteristics:  
i. The outer epithelium, which is lipophilic in 
nature; 
ii. The stroma, which constitutes approximately 
90% of the thickness of cornea and is 
hydrophilic; and 
iii. The inner endothelium consisting of a single 
layer of flattened epithelium like cells. Since, 
the cornea has both hydrophilic and lipophilic 
structures, it presents an effective barrier to the 
absorption of both hydrophilic and lipophilic 
compounds. 
Another serious route for the elimination of topically 
applied drugs from the precorneal area is the nasal 
cavity, with its larger surface area and a high 
permeability of the nasal mucosal membrane is prone 
to absorption into systemic circulation through the 
nasal mucosal lining, which is continuous with the 
conjunctival sac. 
 
Formulation approaches to improve ocular 
bioavailability 
Various approaches that have been attempted to 
increase the bioavailability and the duration of 
therapeutic action of ocular drugs can be divided into 
two categories. The first is based on use of the drug 
delivery systems, which provide the controlled and 
continuous delivery of ophthalmic drugs.  The second 
involves, minimizing precorneal drug loss. Some of the 
requisites of Controlled Ocular Delivery Systems are: 
1. To overcome the side effects of pulsed dosing 
produced by conventional systems. 
2. To provide sustained and controlled drug 
delivery. 
3. To increase ocular bioavailability of drug by 
increasing corneal contact time. 
4. To provide targeting within the ocular globes so 
as to prevent the loss to other ocular sites. 
5. To circumvent the protective barriers like 
drainage, lacrimation and diversion of 
exogenous chemicals into systemic circulation 
by conjunctiva. 
6. To provide comfort and compliance to the 
patient and yet improve the therapeutic 
performance of the drug over conventional 
systems. 
7. To provide better housing of the delivery 
system in the eye so that the loss to other tissues 
besides cornea is prevented. 
The preceding summary demonstrated that the 
formulator faces many constraints and prerequisites 
when developing a modified-release topical ophthalmic 
drug. In addition to the traditional requirements of oral 
drugs for safety, efficacy, and stability, ophthalmic 
products must exhibit additional properties. The 
regulatory demands for new ophthalmic chemical 
entities are, most of the time, outweighed by the 
development efforts and costs compared to the size of 
the ophthalmic market. Indeed, because of the small 
size of the ophthalmic market, it is rather unrealistic to 
think that manufacturers would develop a totally new 
chemical entity specifically for ophthalmic use since 
the return on investment—if any—would be very slow. 
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However, some derivatives have appeared in recent 
times, e.g., timolol base hemihydrate instead of timolol 
maleate [14]. Therefore, in terms of developing a 
modified-release ophthalmic drug delivery system, the 
formulator usually attempts to modify the formulation 
to optimize the release and delivery of an existing drug. 
Primary approaches attempt to slow down the 
elimination of the active ingredient drained by the tear 
flow. 
 
Viscous Solutions and Hydrogels 
Viscous solutions and hydrogels, based upon the 
addition of hydrocolloids to simpler aqueous solutions, 
are the most common formulations. There is no clear-
cut frontier between very viscous solutions and gels in 
terms of biopharmaceutical results. However, 
preformed gels are administered in the same way as an 
ointment, which is less convenient for the patient than 
the instillation of a viscous drop. The most common 
polymers used in viscous solutions are cellulose 
derivatives, carbomers, polysaccharides, and, recently, 
hyaluronic acid. The advantage offered by this last 
product could be dependent upon the active ingredient 
and the formulation environment [15]. Polyvinyl 
alcohol and polyvinyl pyrolidone are also used in 
ophthalmic drugs. Gels permit longer residence time in 
the precorneal area than viscous solutions. This has 
encouraged researchers to work on formulations that 
would be (viscous) solutions in the drug vials but 
would gel in the conjunctival cul-de-sac. 
Three main mechanisms have been explored to induce 
the sol/gel transition in the conjunctival pouch, namely 
a change in pH, a change in temperature, or a change in 
ionic environment [16]. Eventually one formulation of 
timolol, which was based on gellan gum that 
underwent a sol/gel transition due to the ionic content 
of the tears, reached the market in 1994 (Timoptic XE) 
[17,18]. 
Phase transition systems are liquid dosage forms which 
shift to gel or solid phase when instilled in the cul-de-
sac. Polymers like Lutrol FC-127, Poloxamer-407 [19] 
whose viscosity increases when its temperature is 
raised to 37 °C. In situ forming gels have been actively 
pursued. Product(s) using the gellan gum technology 
[20], and with polymer associations like those reported 
by Kumar et al., 1994 [21], and Smart Geltechnology 
[22] are examples of technologies that use this 
approach. This field of intricately entangled polymers 
seems promising since new “patentable” entities might 
be obtained through in-depth studies of associations of 
well-established products. The aqueous formulations of 
such mixtures exhibit changes in physical properties, 
i.e., sol gel transformation, with changes in the 
environment, e.g., temperature,pH, or ionic strength. 
 
Bioadhesives 
It offer several advantages like localizing a dosage 
form within a particular region, increasing drug 
bioavailability, promoting contact with surface for 
longer time, reduce dosage frequency. Several 
synthetic and natural polymers are used for this 
purpose like sodium hyaluronate, chondroitin sulphate 
(natural polymers) and various polyacrylate, carbopols 
(synthetic polymers). A good bioadhesive should 
exhibit a near zero contact angle to allow maximum 
contact with the mucin coat [23]. .  
 
Soft contact lenses 
The rationale for corneal contact devices has not been 
fully explored in therapy. It is generally accepted that 
soft contact lenses can act as a reservoir for drugs, 
providing improved release of the therapeutic agent. 
Presoaked lenses are considered a more efficient and 
reliable delivery system. Imprinted soft contact lenses 
are promising drug devices able to provide greater and 
more sustained drug concentrations in tear fluid with 
lower doses than conventional eye drops [24]. 
 
Ocular iontophoresis 
 Iontophoresis is a process by which the direct current 
drives ions into cell or tissues. Antibiotics, antifungals 
have been tried by this method [25]. Recent progress in 
the technology of the associated hardware has 
stimulated interest in a renewal of its use in 
ophthalmology. 
 
Collagen shields 
Friedburg et al. (1991) [26] developed collagen shields 
to promote wound healing and perhaps more 
importantly to deliver a variety of medications to the 
cornea and other ocular tissues. For drug delivery, the 
shields are rehydrated in aqueous solution of the drug 
whereby the drug is absorbed by the protein matrix and 
is released once the shield dissolves in the eye. 
However, their size and the constraints they impose on 
vision render them impractical for a new drug delivery 
system. Suspensions of collagen microparticulates 
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(e.g., Collasomes or Lacrisomes) might be better 
accepted [27]. 
 
Pseudolatices 
 These are a new class of polymeric colloidal 
dispersion and film forming agents used for topical 
applications into the animals and human beings for 
sustaining the drug activity in vivo [28]. 
 
Ocular penetration enhancer 
 Penetration enhancers like actin filament inhibitors; 
surfactants, bile salts, etc. have been used to increase 
the bioavailability of topically applied proteins and 
peptides [29].  
 
Ocular inserts and implants 
Various erodible implants marketed to date like 
Lacrisert, Soluble ocular drug insert are made of 
mainly collagen, fibrin, HPMC, etc. Two products Alza 
Ocusert [30] and Merck Lacrisert [20], have been 
marketed, although Ocusert is no longer sold. Ocusert 
was an insoluble delicate sandwich technology. Filled 
with suf.cient pilocarpine for 1 week’s use, whereas 
Lacrisert is a soluble minirod of hydroxypropyl 
cellulose, nonmedicated and dissolving within 24 h to 
treat dry-eye syndromes [20]. Other inserts are more 
like implants to be placed in the eye tissues by surgery.  
 
Dispersed Systems 
Dispersed systems based on liposomes, nanoparticles, 
or nanocapsules have been extensively studied for 
potential ophthalmic use [31, 32]. The development of 
marketable products based on these nano products has 
been very challenging and a definitive technology has 
not yet been established. The major issues for this type 
of delivery system include: percentage of dispersed 
phase/entrapment coefficient problem (i.e., how much 
of the active ingredient will be present in a drop of the 
final product), stability and shelf life, antimicrobial 
preservation, tolerance of the used surfactants, and, last 
but not least, large-scale manufacture of sterile 
preparations. Nanosized systems based on liposomes, 
nanoparticles, and nanocapsules have been extensively 
studied and published and call the ophthalmic 
formulator’s attention. Beyond the problem of the 
entrapment percentage of the active pharmaceutical 
ingredient, the retention of these particles in the 
conjunctival pouch is a key consideration. This 
retention must be effective in providing an extended 
source of active and to allow the drug to leak out from 
the dispersed phase before the instilled formulation is 
drained away from the precorneal area. Positively 
charged liposomes were described to have a greater 
affinity for ocular tissues [33]. A possible vehicle to 
administer these delicate nanosystems could be a gel, 
as was described for liposomes [34]. Microemulsions 
might be systems of future interest, with the basic 
caveats concerning sterile manufacturing, long-term 
stability, patient tolerance vis-a`-vis any surfactant, and 
the difficulty to adequately preserve a biphasic system. 
Pilocarpine was described to largely benefit from such 
a formulation, and cyclosporine is a potential candidate 
for it [35]. 
Nanoparticles for ocular drug delivery 
Nanoparticles are solid, colloidal particles consisting of 
macromolecular substances that vary in size from 10 
nm to 1000 nm. The drug of interest is dissolved, 
entrapped, adsorbed, attached or encapsulated into the 
nanoparticle matrix. Depending on the method of 
preparation, nanoparticles, nanospheres or 
nanocapsules can be obtained with different properties 
and release characteristics for the encapsulated 
therapeutic agent [36, 37]. Nanocapsules are vesicular 
systems in which the drug is confined to a cavity 
surrounded by a polymer membrane, whereas 
nanospheres are matrix systems in which the drug is 
physically and uniformly dispersed. 
The utility of nanoparticles as an ocular drug delivery 
system may depend on [38] (a) optimizing lipophilic-
hydrophilic properties of the polymer-drug system, (b) 
optimizing rates of biodegradation in the precorneal 
pocket, and (c) increasing retention efficiency in the 
precorneal pocket. It is highly desirable to formulate 
the particles with bioadhesive materials in order to 
enhance the retention time of the particles in the ocular 
cul-de-sac. Without bioadhesion, nanoparticles could 
be eliminated as quickly as aqueous solutions from the 
precorneal site. Bioadhesive systems can be either 
polymeric solutions [39] or particulate systems [40].  
Nanoparticles represent promising drug carriers for 
ophthalmic applications. After optimal binding to these 
particles, the drug absorption in the eye is enhanced 
significantly in comparison to eye drop solutions owing 
to the much slower ocular elimination rate of particles. 
Smaller particles are better tolerated by the patients 
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than larger particles therefore nanoparticles may 
represent very comfortable ophthalmic prolonged 
action delivery systems.  
Biodegradable polymer nanoparticles have great 
potential as drug delivery devices for the eye. The 
formulation of biodegradable polymers as colloidal 
systems holds significant promise for ophthalmic drug 
delivery [41]. A colloidal system is suitable for poorly 
water-soluble drugs, and would allow drop-wise 
administration while maintaining the drug activity at 
the site of action. Additionally, surface-modified 
nanoparticulate carriers may be used to accommodate a 
wide variety of actives. Although several synthetic 
methods and drug loading techniques are reported to be 
safe and reproducible, no procedure for the formulation 
of drug-loaded nanoparticles has yet been standardized. 
The major developmental issues in the case of 
nanoparticles include formulation stability, particle size 
uniformity, control of drug release rate, and large-scale 
manufacture of sterile preparations [42].  Nanosystems 
having surface-segregated chitosan or 
polyethyleneglycol have been found to be relatively 
stable and also efficient at overcoming mucosal 
barriers [43].  
 
Polymers used in the preparation of nanoparticles 
Nanoparticles made of non biodegradable polymers are 
neither digested by enzymes nor degraded in vivo 
through a chemical pathway [44]. The risk of chronic 
toxicity due to the intracellular overloading of 
nondegradable polymers would be a limitation of their 
systemic administration to human beings, making these 
materials more suitable for removable inserts or 
implants. Erodible systems have an inherent advantage 
over other systems in that the self-eroding process of 
the hydrolyzable polymer obviates the need for their 
removal or retrieval after the drug is delivered. Upon 
the administration of particle suspension in the eyes, 
particles reside at the delivery site and the drug is 
released from the polymer matrix through diffusion, 
erosion, ion exchange, or combinations thereof [38]. 
Few examples of reported polymers for successful 
preparation of nanoparticle are described below:  
 
1. Polymethylmethacrylate (PMMA) nanoparticles, 
which are excellent adjuvants for vaccines, can be 
produced by the emulsion polymerization technique. In 
this process, monomeric methylmethacrylate is 
dissolved in a concentration range of 0.1–1.5% in water 
or phosphate–buffered saline or a solution or 
suspension of drugs or antigens [45]. But nanoparticles 
made of polyacrylamide or PMMA do not degrade 
either biologically or enzymatically, which makes them 
less attractive for ophthalmic use. 
 
2. Cellulose acetate phthalate has been used for in situ 
gelling of latex nanoparticles [46] [42]. The preparation 
of these latex particles involves emulsification of 
polymer in organic solvent followed by solvent 
evaporation. This latex suspension, upon coming in 
contact with the lacrimal fluid at pH 7.2–7.4, gels in 
situ, thus averting rapid washout of the instilled 
solution from the eye. But the disadvantage of these 
preparations is vision blurring. 
 
3. PACA (polyacryl-cyanoacrylate) particles possess 
properties of biodegradation and bioadhesion, making 
them of considerable interest as possible drug carriers 
for controlled ocular drug delivery and drug targeting. 
Wood et al [47] showed that PACA nanoparticles were 
able to adhere to the corneal and conjunctival surfaces, 
which represent their mucoadhesion property. This 
polymer has the ability to entangle in the mucin matrix 
and form a noncovalent or ionic bond with the mucin 
layer of the conjunctiva. Betaxolol [48] and amikacin 
sulfate [49] loaded polyalkylcyanoacrylate has shown 
good result. Polyalkylcyanoacrylate (PACA) 
nanoparticles and nanocapsules have been shown to 
improve and prolong the corneal penetration of 
hydrophilic and lipophilic drugs. Despite these positive 
results, the potential of the PACA nanoparticles is 
limited because they cause disruption to the corneal 
epithelium cell membrane [50]. 
4. poly-_-caprolactone (PECL) nanocapsules may serve 
as superior polymer systems for ocular drug delivery 
[51, 52]. Marchal-Heussler et al. [52] compared 
nanoparticles prepared by using PACA, PECL, and 
polylacticco-glycolic acid with betaxolol as model 
drug. It was shown that the PECL nanoparticles yielded 
the highest pharmacological effect. This was believed 
to be due to the agglomeration of these nanoparticles in 
the conjunctival sac. Nanocapsules for topical ocular 
delivery of cyclosporin A (CyA) comprising an oily 
core (Miglyol 840) and a poly-€-caprolactone coating 
increased the corneal levels of the drug by 5 times 
compared to the oily solution of the drug when 
administered to the cul-de-sac of fully awake New 
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Zealand white rabbits [53]. Poly-_-caprolactone 
nanocapsules also showed good performance in 
increasing the ocular availability of drugs such as 
metipranolol  [51] and betaxolol [52] while suppressing 
their systemic absorption. An alternative colloidal 
system, poly-∈-caprolactone (PECL) nanocapsule have 
shown the usefulness as ocular drug delivery systems. 
More specifically these nanocapsules have been shown 
to increase ocular penetration of lipophilic drugs such 
as metipranolol, betaxolol, amphotericin-B. Calvo et 
al., 1996 [53] observed that PECL nanocapsules are 
specifically taken by the corneal epithelium cells 
without damaging the cell membrane. 
 
5. Cationic polymer chitosan (CS) has attracted a great 
deal of attention because of its unique properties, such 
as acceptable biocompatibility and biodegradability 
[54, 55].  The bioavailability of nanoparticles coated 
with poly-l-lysine and chitosan (both have positive 
charge) were compared to that of noncoated 
nanoparticles. It was suggested that the specific nature 
of chitosan was responsible for bioavailability 
improvement rather than the charge. CScoated 
nanocapsules were more efficient at enhancing the 
intraocular penetration of some specific drugs [56, 57]. 
 
6.  Eudragit® Retard polymer nanoparticle suspensions 
have been investigated as a carrier system for the 
ophthalmic release of nonsteroidal antiinflammatory 
drugs, such as ibuprofen and flurbiprofen [58, 59]. 
Polymeric nanoparticle suspensions will be prepared 
from inert polymer resins (Eudragit® RS100, RS, and 
RL100, RL). When loaded with drugs, these resins are 
proposed as delivery systems to prolong the release and 
improve ocular availability of the drug. Polymer 
nanoparticles proposed are reported to be devoid of any 
irritant effect on cornea, iris, and conjunctiva and thus 
appear to be a suitable inert carrier for ophthalmic drug 
delivery. 
 
7. Polybutylcyanoacrylate nanoparticle delivery system 
for pilocarpine nitrate has been evaluated in 
comparison to the solution of the drug for 
pharmacokinetic and pharmacodynamic aspects [60]. 
Diepold et al. [61] incorporated pilocarpine into 
polybutylcyanoacrylate nanoparticles and evaluated the 
aqueous humor drug levels and the intraocular 
pressure-lowering effects using three models (the 
water-loading model, the alpha-chymotrypsin model, 
and the betamethasone model) in rabbits. The miotic 
response was enhanced by about 33% while the miotic 
time increased from 180 to 240 minutes for 
nanoparticles compared to the control solution. 
 
8. Acyclovir-loaded PEG-coated polyethyl-2-
cyanoacrylate (PECA) nanospheres prepared by 
emulsion polymerization technique showed increased 
drug levels in the aqueous humor compared to the free 
drug suspension in the rabbits [62]. 
  
9. Polylactide and polylactide-co-glycolide 
biopolymers in the molecular weight range of 3000–
109,000 have been employed in the preparation of 
microparticulate systems for intravitreal administration 
of acyclovir [63]. Spray-drying technique was 
employed for the preparation and the in vivo evaluation 
was performed by intravitreal administration in rabbits. 
The poly-d, l-lactide microspheres of acyclovir were 
more efficient compared to the free drug in providing a 
sustained release of the drug in the vitreous humor in 
rabbits. A promising result is reported by Agnihotri et 
al., 2008 [64] for polymeric nanoparticle suspensions 
(NS) which was prepared from poly (lactide-co-
glycolide) and poly (lactide-co-glycolide-leucine) 
{poly [Lac (Glc-Leu)]} biodegradable polymers and 
loaded with diclofenac sodium.  
  
Conclusion 
Particulate systems have the potential to become 
promising systems for ophthalmic drug delivery. The 
potential for success of nanoparticles in ophthalmic 
drug delivery has been demonstrated in a number of 
studies of either hydrophilic or hydrophobic drugs. 
Though formulation stability, control of particle size, 
control of the rate of drug release, and large-scale 
manufacture of sterile preparations are some of the 
major issues involved in the development of 
ophthalmic particulate formulations. In spite of that the 
successful results of various researchers establishing 
the potential of nanoparticles for ocular drug delivery. 
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